Just weeks after regaining rights to a bispecific antibody from Novartis, Xencor has entered into a research collaboration and license agreement with Genentech to develop and commercialise interleukin-15 (IL-15) therapeutics. The potential US$460 M deal includes cancer immunotherapy XmAb24306, as well as a research programme for additional IL-15 drug candidates. The deal will also allow the companies to explore combination treatments of IL-15 assets with Genentech’s oncology portfolio and/or Xencor’s growing internal pipeline of bispecific antibodies.